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Background: Budesonide/formoterol maintenance and reliever therapy (Symbicort
SMARTs) improves asthma control compared with fixed-dose inhaled corticosteroid/
long-acting b2-agonist (ICS/LABA) regimens, but its efficacy has not been assessed in
comparison with sustained high-dose salmeterol/fluticasone (SeretideTM) plus a short-
acting b2-agonist (SABA).
Methods: Patients (N ¼ 2309) with symptomatic asthma (aged X12 years; forced
expiratory volume in 1 s X50% predicted), who had experienced an asthma exacerbation
in the previous year, were randomised to receive budesonide/formoterol 160/4.5 mg
two inhalations twice daily and as needed, or one inhalation of salmeterol/fluticasone
50/500 mg twice daily plus terbutaline as needed, for 6 months.
Results: Time to first severe exacerbation, the pre-specified primary outcome, was not
significantly prolonged (risk ratio 0.82; 95% confidence interval 0.63, 1.05). Budesonide/
formoterol maintenance and reliever therapy reduced total exacerbations from 31 to 25
events/100 patients/year (P ¼ 0.039), and exacerbations requiring hospitalisation/
emergency room (ER) treatment from 13 to 9 events/100 patients/year (P ¼ 0.046).Published by Elsevier Ltd.
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J. Bousquet et al.2438The treatments showed no difference in measures of lung function or asthma symptoms.
The mean dose of ICS received was lower using budesonide/formoterol maintenance and
reliever therapy (792 mg/day budesonide [1238 mg/day beclomethasone dipropionate (BDP)
equivalent] versus 1000mg/day fluticasone [2000 mg/day BDP equivalent] with salmeterol/
fluticasone therapy; Po0.0001). Both treatments were well tolerated.
Conclusion: In the treatment of uncontrolled asthma, budesonide/formoterol mainte-
nance and reliever therapy reduces the incidence of severe asthma exacerbations and
hospitalisation/ER treatment with similar daily symptom control compared with sustained
high-dose salmeterol/fluticasone plus SABA. This benefit is achieved with substantially less
ICS exposure.
& 2007 Published by Elsevier Ltd.Introduction
The aim of modern asthma management is to improve
control of the disease. This is reflected in guidance
produced for healthcare professionals with the intention of
improving patient care.1,2 Furthermore, it should provide
patients with an effective means of addressing deteriora-
tions in asthma, so that severe exacerbations can be
averted.3–6
When control of asthma is not achieved in adults using
low-dose inhaled corticosteroids (ICS), ICS/long-acting
b2-agonist (LABA) combination therapy is the recommended
treatment approach.6–11 Surveys of asthma, however, have
shown that the majority of patients using an ICS/LABA
combination or ICS alone still require daily short-acting
b2-agonist (SABA) therapy, with high proportions reporting
daytime symptoms, awakenings and hospital admissions due
to asthma.3–5,12
The challenge of residual symptoms in adults using ICS/LABA
combinations can now be managed in two ways. One option
is to increase the maintenance dose of the fixed-dose
ICS/LABA combination (budesonide/formoterol or salmeter-
ol/fluticasone), with the aim of progressively stabilising the
underlying disease process to minimise the need for short-
acting reliever therapy.7,13,14 An alternative, more patient-
centred option, is the use of budesonide/formoterol for
both maintenance and relief. This approach is possible
because the rapid onset of formoterol15 allows its use for
relief, unlike combination products containing the slower-
acting bronchodilator, salmeterol.16
Use of budesonide/formoterol maintenance and reliever
therapy (Symbicort SMARTs) relies on rapid as-needed
adjustments in ICS/LABA, as opposed to SABA therapy, to
fine-tune asthma control. This approach has the advantage
over fixed-dose ICS/LABA plus SABA of substantially reducing
severe exacerbations.17–20 This new management approach
is now endorsed in the updated Global Initiative for Asthma
(GINA) guidelines as an effective treatment strategy for
preventing asthma exacerbations and improving asthma
control.6
In a large, 6-month, double-blind study, treatment with
budesonide/formoterol 160/4.5 mg twice daily (bid) plus as
needed reduced exacerbation rates by 28–39% compared
with either budesonide/formoterol 320/9 mg bid or salme-
terol/fluticasone 250/50 mg bid plus SABA as needed.20 This
result was also replicated in a 1-year, open-label, rando-mised study performed in a clinical setting, mirroring normal
treatment practice, which showed that dose titration of
salmeterol/fluticasone combination therapy was less effec-
tive than budesonide/formoterol maintenance and reliever
therapy, with the latter approach reducing the rate of
severe asthma exacerbations by 22%.19 Although the open-
label study allowed maintenance doses to be adjusted in line
with clinician judgement, only 40% of salmeterol/flutica-
sone-treated patients were titrated to the highest possible
dose (50/500 mg bid), which may have resulted in less than
optimal control. In the Gaining Optimal Asthma Control
(GOAL) study, across all strata, 68% of patients receiving
salmeterol/fluticasone were on the highest dose at the end
of treatment.7 However, as budesonide/formoterol main-
tenance and reliever therapy has not been tested against
sustained high-dose salmeterol/fluticasone therapy, a direct
comparison is warranted.
This study assessed the efficacy of budesonide/formoterol
2 160/4.5 mg bid plus as needed, compared with salmeter-
ol/fluticasone (50/500 mg bid) plus SABA as needed, in a
double-blind setting.Methods
Study design
This was a 6-month, randomised, double-blind, parallel-
group, multinational study (study code D589 0C00002),
comprising 184 centres in 17 countries. The study was
performed in accordance with the Declaration of Helsinki
and Good Clinical Practice guidelines and approved by
independent ethics committees. Written consent was
obtained from all patients, and parents or guardians of
adolescents. The first patient was enrolled on 2 May 2005
and the last patient completed the study on 29 May 2006.
Patients visited the clinic at the beginning and end of run-
in (visits 1–2), and after 4, 13 and 26 weeks of treatment
(visits 3–5). During the 2-week run-in period, patients used
their regular maintenance dose of ICS (in combination with a
LABA if used as maintenance prior to study entry), plus
terbutaline (Bricanyls Turbuhalers, AstraZeneca, Sweden)
as needed. After run-in, eligible patients were randomised
to receive either budesonide/formoterol (Symbicorts
Turbuhalers, AstraZeneca, Sweden) 2 160/4.5 mg bid,
plus as needed (budesonide/formoterol maintenance and
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Figure 1 Patient flow. *One patient discontinued treatment but continued in the study; all data from this patient are included in
the efficacy analysis in accordance with the full analysis set principle.
Budesonide/formoterol for maintenance and relief 2439reliever therapy), or salmeterol/fluticasone (SeretideTM
DiskusTM, GlaxoSmithKline, UK) 50/500 mg bid, plus terbuta-
line 0.4mg/inhalation for symptom relief (Figure 1).
Randomisation codes were sequentially assigned in balanced
blocks from a computer-generated list at AstraZeneca R&D,
Lund, Sweden. Patients were randomised strictly sequen-
tially as they became eligible. Maintenance and as-needed
medication were administered in a blinded double-dummy
fashion, with each subject receiving two inhalers for
maintenance (one Turbuhaler [red dot], containing budeso-
nide/formoterol or placebo; one DiskusTM, containing
salmeterol/fluticasone or placebo) and one Turbuhalers
(white) containing budesonide/formoterol or terbutaline
for relief.Study subjects
Outpatients aged 12 years or more, with persistent asthma,
who had been treated with ICS alone (800–1600 mg/day) or
ICS (400–1000 mg/day) in combination with LABA for at least
3 months prior to study entry, were eligible for inclusion. All
eligible patients had a pre-bronchodilator forced expiratory
volume in 1 s (FEV1) X50% of predicted normal value, with
X12% reversibility following 1.0mg terbutaline, and had
experienced one or more clinically important asthma
exacerbations (as judged by the clinician) in the previous
12 months (but none in the month before enrolment). To be
eligible for randomisation at the end of run-in, patients had
to have used as-needed terbutaline on X5 of the previous
7 days, with no more than eight inhalations in any single day.Exclusion criteria included recent respiratory infection, use
of systemic corticosteroids within 30 days of study entry, use
of any b-blocking agent (including eye drops) and a smoking
history of X10 pack-years.Assessments
The primary outcome was time to first severe exacerbation,
defined as deterioration in asthma leading to hospitalisa-
tion/emergency room (ER) treatment and/or oral corticos-
teroid treatment for at least 3 days.21 Secondary outcomes
included the rate of severe exacerbations (as the same
composite), the time to first hospitalisation/ER treatment
and the rate of hospitalisation/ER treatments.
Measures of daily asthma control, including peak expira-
tory flow, reliever use, asthma symptoms and nights with
awakenings due to asthma symptoms, were recorded by
patients in daily asthma diaries. From these assessments, a
composite measure of asthma control days (day and night
with no asthma symptoms, no awakenings due to asthma
symptoms and no use of as-needed medication) was derived.
At clinic visits, adherence was checked by investigators,
spirometry (FEV1) was performed and patients completed an
Asthma Control Questionnaire (5-item version; ACQ-5),
consisting of five questions on symptom control (excluding
responses based on FEV1 and as-needed medication use,
which are included in the ACQ-7), each scored on a scale of
0–6, where 0 represents good control and 6 represents poor
control. The overall score from the ACQ-5 was the mean of
the five responses.
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J. Bousquet et al.2440Total use of as-needed inhalations recorded in patient
diaries was also used to evaluate the mean daily dose of ICS
with budesonide/formoterol maintenance and reliever
therapy in delivered budesonide and beclomethasone
dipropionate (BDP)-equivalent doses.6Statistical analysis
The primary objective was to compare the time to first
severe asthma exacerbation between treatment groups. A
total of 985 randomised and evaluable patients per treat-
ment group were required for a log-rank test (at the two-
sided 5% significance level) to have a 90% chance of
detecting a between-group difference, assuming a true
difference of 11% versus 16% in the patients who experi-
enced a severe asthma exacerbation. All patients for whom
data were collected after randomisation were included in
the full analysis set. Safety analyses were based on all
patients taking at least one dose of study medication.
Time to first severe exacerbation was described using
Kaplan–Meier curves, and treatment groups were compared
using a Cox proportional hazards model, stratified by
country, with treatment as a factor. The total number of
severe exacerbations was compared between treatment
groups using a Poisson regression model with treatment and
country as factors, and time in study as an offset variable.
The same methods were used to perform an additional post
hoc analysis comparing differences in exacerbation risk
between the two groups in relation to single days with 42,
44, 46 and 48 inhalations of as-needed reliever medica-
tion. Other efficacy measures, including spirometry, peak
expiratory flow, asthma symptoms, as-needed medication
use and ACQ-5 score, were compared between groups as
changes from baseline using analysis of variance, with
treatment and country as factors and baseline as a covariate.Table 1 Baseline characteristics of patients.
Characteristic Budeson
mainten
(N ¼ 11
Male, n (%) 443 (38
Mean age, years (range) 40 (12–
Time since diagnosis*, years (range) 14 (1–6
Exacerbations during last 12 months (range) 1.8 (1–1
FEV1, l (range) 2.08 (0.
FEV1, % predicted normal (range) 70.2 (45
FEV1 reversibility, % (range) 23.9 (7–
Smoking status
Never, n (%) 949 (82
Previous, n (%) 154 (13
Smokers, n (%) 51 (4)
ICS use at entry, mg/day delivered dose (range) 705 (25
Inhaled LABA use at entry, n (%) 645 (56
Data are means unless otherwise indicated; *median value.
SABA ¼ short-acting b2-agonist.
FEV1 ¼ forced expiratory volume in 1 s.
ICS ¼ inhaled corticosteroid.
LABA ¼ long-acting b2-agonist.Results
Patient profile
Of the 3346 patients enrolled, 2309 were randomised
and 2304 were included in the full analysis set (see
Figure 1 for patient flow). Baseline characteristics were
comparable between the two treatment groups (Table 1).
Self-reported adherence to maintenance medication was
high (mean use was 98% according to patient diary cards in
both groups).Exacerbations
Time to first exacerbation was not significantly different
between treatment groups (hazard ratio 0.82; P ¼ 0.12).
However, Kaplan–Meier plots of time to first and second
exacerbation (Figure 2) show that budesonide/formoterol
maintenance and reliever therapy tended to prolong the
time to the first and repeat exacerbations. This was
reflected in a 21% reduction in overall exacerbation rate
versus high-dose salmeterol/fluticasone (25 versus 31
events/100 patients/year; P ¼ 0.039; Table 2). The risk of
a hospitalisation/ER treatment for asthma was also de-
creased versus high-dose salmeterol/fluticasone plus SABA
(hazard ratio 0.64; P ¼ 0.031), and a 31% reduction
in the rate of hospitalisation/ER treatment was seen
with budesonide/formoterol maintenance and reliever
therapy (9 versus 13 events/100 patients/year, respectively;
P ¼ 0.046; Table 2). The 21% reduction in the rate
of exacerbations seen with budesonide/formoterol main-
tenance and reliever therapy compared with high-
dose salmeterol/fluticasone was consistent (71%)
for patients pre-exposed or not exposed to LABA at study
entry.ide/formoterol
ance and reliever therapy
54)
High-dose salmeterol/
fluticasone + SABA
(N ¼ 1155)
) 444 (38)
80) 39 (12–80)
7) 13 (1–77)
0) 1.9 (1–24)
60–4.65) 2.10 (0.72–4.89)
–114) 71.0 (45–222)
103) 23.9 (7–95)
) 952 (82)
) 151 (13)
52 (5)
0–1600) 720 (200–2000)
) 622 (54)
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Figure 2 Kaplan–Meier plots of (a) time to first severe asthma exacerbation and (b) time to second severe exacerbation. The risk of
a first exacerbation was not different between the treatments with statistical significance (P ¼ 0.12). SMART ¼ budesonide/
formoterol maintenance and reliever therapy. SAL/FLU+SABA ¼ high-dose salmeterol/fluticasone + short-acting b2-agonist.
Table 2 Burden of severe asthma exacerbations.
Treatment group Reduction in the risk and
rate (%) of exacerbations
with budesonide/formoterol
maintenance and reliever
therapy (95% CI); P-value
Budesonide/formoterol
maintenance and
reliever therapy
(N ¼ 1151)
High-dose salmeterol/
fluticasone + SABA
(N ¼ 1153)
All patients (intention-to-treat population)
Severe asthma exacerbations (all definitions)
Patients with event, n (%) 108 (9.4) 130 (11.3) 18a (–5, 37); P ¼ 0.12*
Rate, events/100 patients/year 25 31 21b (1, 37); P ¼ 0.039*
Total number of events# 137 173
ER visits or hospitalisations
Patients with event, n (%) 39 (3.4) 59 (5.1) 36a (4, 57); P ¼ 0.031*
Rate, events/100 patients/year 9 13 31b (1, 51); P ¼ 0.046*
Total events# 51 73
Patient subgroup with use of 44 inhalations of reliever medication on at least one study day
Number within subgroup, n (%) 305 (26.5) 333 (28.9)
Severe asthma exacerbations following the first use of 44 inhalations/day (all definitions)
Patients with event, n (% of subgroup) 46 (15.1) 80 (24.0)
Rate, events/100 patients/year in subgroup 54 92 41b (19, 57); P ¼ 0.0012y
ER visits or hospitalisations following the first use of 44 inhalations/day
Patients with event, n (% of subgroup) 17 (5.6) 39 (11.7)
Rate, events/100 patients/year in subgroup 20 42 53b (22, 72); P ¼ 0.0037y
aTreatment comparisons from a Cox proportional hazards model of time to first severe asthma exacerbation.
bComparison of relative rates from a Poisson regression; *a priori analysis; ypost hoc analysis; #descriptive statistics only.
Budesonide/formoterol for maintenance and relief 2441Pattern of reliever use in relation to exacerbations
Days with a high number of as-needed inhalations of44,46
and 48 reliever inhalations/day (indicating periods with
poorly controlled asthma) occurred with salmeterol/flutica-
sone plus SABA in 333 (29%), 151 (13%) and 49 (4%) patients,
and with budesonide/formoterol maintenance and reliever
therapy in 305 (27%), 106 (9%) and 32 (3%) patients,
respectively. The incidence of severe exacerbations inassociation with this pattern of high as-needed use was
reduced with budesonide/formoterol maintenance and
reliever therapy more than with high-dose salmeterol/
fluticasone plus SABA. Kaplan–Meier plots in Figure 3 show
the time to first severe exacerbation in the 28-day period
after the first day of high reliever use, revealing that, at
times of increasingly poor asthma control, budesonide/
formoterol maintenance and reliever therapy provided added
protection from exacerbations compared with high-dose
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Figure 3 Kaplan–Meier plots showing the percentage of patients with X1 exacerbation in the month following the first day with
(a) 42, (b) 44, (c) 46 and (d) 48 inhalations/day of as-needed medication. SMART ¼ budesonide/formoterol maintenance and
reliever therapy. SAL/FLU + SABA ¼ high-dose salmeterol/fluticasone + short-acting b2-agonist. inh. ¼ inhalations.
J. Bousquet et al.2442salmeterol/fluticasone plus SABA. The incidence of exacer-
bations following the first day with 44 inhalations of
reliever therapy are shown in Table 2.
Measures of control
Table 3 shows similar improvements in daily symptom
control. Asthma control days increased in both treatment
groups, from 6.3% and 5.8% at baseline to 44.0% and 44.9% in
the budesonide/formoterol and high-dose salmeterol/fluti-
casone groups, respectively. Similarly, ACQ-5 scores de-
creased in both groups with no significant difference
between groups, indicating similar clinically relevant im-
provements in asthma control (Table 3).22
FEV1 increased in both groups, from 2.29 to 2.52 l with
budesonide/formoterol and from 2.27 to 2.49 l with high-
dose salmeterol/fluticasone, with no difference between
the treatments.
Study drug use and treatment cost
No as-needed medication use occurred on 59% of days in
both treatment groups, although patients used a mean of
0.95 and 1.01 inhalations/day in the budesonide/formoterol
and salmeterol/fluticasone groups, respectively. Mean daily
doses of ICS were substantially lower in the budesonide/
formoterol group than in the high-dose salmeterol/flutica-
sone group. With salmeterol/fluticasone, the fluticasone
dose was fixed at 1000 mg/day (2000 mg BDP equivalent), andin the budesonide/formoterol maintenance and reliever
therapy group, the mean budesonide dose was 792 mg/day
(1238 mg BDP equivalent), representing an average 38%
reduction in BDP-equivalent dose (Po0.0001).
There were 764 days of oral steroid use due to
exacerbations among 88 (7.6%) of the patients in the
budesonide/formoterol group, compared with 990 days
among 108 (9.4%) patients in the salmeterol/fluticasone
group. This indicates a substantial overall reduction in the
necessity for oral steroid use due to exacerbation in the
budesonide/formoterol group.
Study drug costs/patient/year were estimated for five
countries participating in the study. The reduced drug load
was associated with reduced drug costs for budesonide/
formoterol maintenance and reliever therapy versus high-
dose salmeterol/fluticasone plus SABA, although this benefit
varied by country. In four of the five countries assessed
(Germany, Spain, Australia and Canada), costs were sig-
nificantly reduced, by 4%, 5%, 11% and 24%, respectively (all
Po0.001 versus salmeterol/fluticasone). No decrease in
cost was seen with budesonide/formoterol maintenance and
reliever therapy in France (1% increase versus salmeterol/
fluticasone; P ¼ 0.10).Safety
The number of patients reporting adverse events (39% with
budesonide/formoterol, 40% with salmeterol/fluticasone)
and serious adverse events (3% with budesonide/formoterol,
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Table 3 Mean outcome measures of daily control and ACQ assessed during run-in and on-treatment.
Treatment group Treatment comparison
(95% CI); P-valuea
Budesonide/formoterol
maintenance and
reliever therapy
(N ¼ 1144)
High-dose salmeterol/
fluticasone + SABA
(N ¼ 1145)
Use of as-needed medication
Total inhalations daily
Run-in 2.23 2.29 –0.04 (–0.12, 0.04);
On-treatment 0.95 1.01 P ¼ 0.36
As-needed free days, %
Run-in 10.3 9.3 –0.80 (–3.6, 1.9);
On-treatment 58.2 58.4 P ¼ 0.56
Asthma symptoms
Total symptom score, 0–6 scale
Run-in 1.87 1.89 0.00 (–0.06, 0.07);
On-treatment 0.98 0.98 P ¼ 0.92
Symptom-free days, %
Run-in 10.7 11.2 –0.50 (–3.3, 2.3);
On-treatment 47.2 48.1 P ¼ 0.73
Awakenings, %
Run-in 32.1 32.2 –1.30 (–2.8, 0.3);
On-treatment 12.0 13.3 P ¼ 0.11
Asthma control days, %
Run-in 6.3 5.8 –1.30 (–4.1, 1.5);
On-treatment 44.0 44.9 P ¼ 0.37
ACQ-5 (0–6 scale)
Run-in 1.84 1.89 –0.02 (–0.07, 0.04);
On-treatment 1.08 1.12 P ¼ 0.59
PEF (l/min)
Morning
Run-in 330.1 329.0 –0.8 (–4.4, 2.8);
On-treatment 359.5 359.4 P ¼ 0.67
Evening
Run-in 336.7 337.7 1.4 (–2.1, 4.9);
On-treatment 362.3 361.7 P ¼ 0.42
Asthma control day ¼ a day and night with no asthma symptoms, no awakenings due to asthma symptoms and no use of as-needed
medication; PEF ¼ peak expiratory flow.
aTreatment comparison using an analysis of variance model with country and treatment as factors and run-in included as a covariate.
Budesonide/formoterol for maintenance and relief 24433% with salmeterol/fluticasone) were similar in both
treatment groups. Discontinuations were rare in both
treatment groups; there were 31 in total (11 with
budesonide/formoterol, 20 with salmeterol/fluticasone).
Discontinuations in the salmeterol/fluticasone group in-
cluded eight reports of events associated with the class
effects of ICS or b2-agonists (dysphonia, oral candidiasis,
oral fungal infection, tremor, tachycardia and palpitations),
compared with only one such report in the budesonide/
formoterol group (headache). One death occurred during
the study (in the budesonide/formoterol group; severe
typhoid fever) but was not considered by the investigator
to be causally related to the study drug.Discussion
This study compared two highly effective asthma treatment
strategies, budesonide/formoterol as maintenance and
reliever therapy, and high-dose salmeterol/fluticasone
(100/1000 mg/day) supplemented with terbutaline as
needed. In both of the study arms, symptoms, lung function
and reliever use all improved, and there was not a
significant difference in the pre-specified primary outcome,
time to first severe exacerbation. There were, however,
significantly greater, and clinically important, reductions in
the overall number of exacerbations and in exacerbations
specified by hospitalisation or ER treatments, by 21% and
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J. Bousquet et al.244431% with budesonide/formoterol maintenance and reliever
therapy versus high-dose salmeterol/fluticasone, respec-
tively. The lack of difference between treatments in time to
first severe exacerbation, in spite of significant differences
in the secondary outcome parameters for severe exacerba-
tions, may be the result of the short duration of the study;
increasing the duration to 12 months may have permitted a
difference to be observed, as has been seen elsewhere.19
In patients randomised to budesonide/formoterol main-
tenance and reliever therapy, 59% of days were free of any
reliever use, which is identical to the percentage of
reliever-free days in those subjects randomised to high-
dose salmeterol/fluticasone. On these days, patients trea-
ted with budesonide/formoterol maintenance and reliever
therapy were managed with half the daily dose of ICS used
by the salmeterol/fluticasone group, i.e. 1000 mg/day versus
2000mg/day BDP equivalents. However, overall, patients
treated with budesonide/formoterol maintenance and re-
liever therapy used a mean of 762 mg/day less than those in
the salmeterol/fluticasone group. The average reliever use
overall was also similar in the two treatment groups, at
approximately one dose/day. The number of days of high
reliever use was small, and was similar in the two study
arms. The absence of overuse and the overall pattern of
reliever use replicate findings in other budesonide/formo-
terol studies. This randomised, blinded study demonstrates
that there is no basis to favour the alternative approach of
high-dose salmeterol/fluticasone treatment on the grounds
that it will improve symptoms and eliminate the inconve-
nience associated with reliever use.
This study has shown that budesonide/formoterol main-
tenance and reliever therapy provides an effective inter-
vention during periods of unstable asthma. Days with an
increased number of as-needed inhalations (42, 44, 46
and 48 inhalations/day) were used to identify periods of
worsening asthma. The pattern of severe exacerbations
following these high-use days revealed that the budesonide/
formoterol maintenance and reliever therapy approach
provided patients with greater protection from severe
exacerbations at times of asthma worsening (Figure 3).
The numbers of exacerbations increased more strikingly
with the level of as-needed use in the high-dose salmeterol/
fluticasone plus SABA group than with budesonide/formo-
terol maintenance and reliever therapy. In both treatment
groups, patients who had used more than four reliever doses
on any single day had a higher than average risk for severe
exacerbation. However, the proportional reduction in severe
exacerbations in those patients using more than four
reliever doses per day was greater in the budesonide/
formoterol group. In this group the use of salmeterol/
fluticasone treatment, rather than budesonide/formoterol
maintenance and reliever therapy (Table 2), was associated
with more than double the rate of hospitalisations/ER
treatments.
This study demonstrates that, despite using moderate to
high doses of ICS/LABA in both treatment groups, episodes
of high reliever use on a single day are still common and can
often be associated with a high risk of imminent exacerba-
tion, but that these exacerbations are not inevitable. The
most common intervention advised in asthma action plans
for such episodes is doubling of ICS, but this often proves
ineffective.23,24 This study has shown that budesonide/formoterol maintenance and reliever therapy, in periods of
increased exacerbation risk, increases ICS/LABA doses in
line with disease activity, which is associated with clear
efficacy benefits.
Taken together, these findings suggest that the greater
the exacerbation risk, the greater the benefit of budeso-
nide/formoterol. It is therefore important to educate
patients about the importance of using their budesonide/
formoterol reliever when asthma symptoms occur.
Reassuringly, despite the substantial reduction in ICS dose
with budesonide/formoterol maintenance and reliever
therapy, no difference was shown between the two regimens
in any aspect of daily symptom control or asthma control
assessed by questionnaire. This reflects the observation that
both treatment groups had effective asthma treatment,
with visible increases in asthma control from run-in. Full
clinical control of symptoms (asthma control days) occurred
in approximately half of the treatment days in both groups
(44–45%); this was nevertheless substantially higher than the
6% of asthma control days at baseline in both groups. Both
treatment strategies were equally well tolerated, confirm-
ing the favourable safety profiles of the two treatment
approaches, as seen in previous studies.19,20
The reduction in the rate of exacerbations with budeso-
nide/formoterol maintenance and reliever therapy com-
pared with high-dose salmeterol/fluticasone was con-
sistently observed (range 21–22% reduction), whether
patients used ICS alone or ICS plus LABA at study entry. This
finding therefore negates the need for a prior trial of ICS/
LABA ahead of implementing the budesonide/formoterol
maintenance and reliever therapy approach. In addition, the
convenience of ICS/LABA combined in one inhaler is
increased further when the same inhaler can be used for
maintenance and relief. These features, coupled with
reduced ICS load and potential savings in treatment costs
with budesonide/formoterol maintenance and reliever
therapy compared with high-dose salmeterol/fluticasone,
should not be overlooked when deciding which treatment
approach to utilise.
The exact mechanisms for increased exacerbation control
with budesonide/formoterol maintenance and reliever
therapy have yet to be fully determined. A detailed
discussion of the potential contribution made by budesonide
and formoterol is beyond the scope of the present article
and readers are referred to a recent review article.25
However, one important factor, supported by current
findings in high as-needed users, is the early increase in
anti-inflammatory treatment provided by as-needed inhala-
tions of budesonide/formoterol during periods of deterior-
ating symptoms. Indeed, use of high-dose budesonide has
been shown to reduce eosinophilic inflammation within a 6-h
period.26 Additional non-genomic effects of as-needed
budesonide have been reported, including rapid airway
vasoconstriction leading to a reduction in airway oede-
ma.25,27,28 Single doses of budesonide/formoterol have also
been shown to provide complete protection from late-phase
bronchoconstrictor responses provoked by allergens, an
effect not fully obtained with budesonide or formoterol
monotherapy.29
When considering as-needed formoterol, switching pa-
tients from terbutaline to formoterol as needed has been
shown to be effective in reducing asthma exacerbations in
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therapy.18 Thus, increasing doses of formoterol in the
presence of ICS is associated with increased protection
from exacerbations.18,30 Higher doses are not recommended
with salmeterol, a partial b2-agonist, which has a plateau in
its efficacy at around 100 mg/day.31,32 In a recent systematic
review of over 4000 patients, comparing single inhaler
combinations containing formoterol or salmeterol at equiva-
lent fixed ICS doses, it was found that exacerbations occur
to the same extent with both combinations but fewer result
in hospitalisation/ER treatment with budesonide/formoter-
ol compared with salmeterol/fluticasone.33 Thus, the great-
er intrinsic efficacy of formoterol may result in it being more
effective in protecting patients during periods of increased
bronchial challenge compared with salmeterol.31,34
Additional beneficial effects on neutrophilic inflammation
with formoterol compared with salmeterol have also been
shown in vitro.35 Whether these effects play any role in
preventing severe exacerbations caused by the viral or
bacterial infections that are associated with neutrophilic
rather than eosinophilic inflammation is currently uncertain.
A potential limitation of the study is the accuracy level of
self-reported medication use. However, a similar pattern of
recorded reliever use occurred in both treatment groups,
with a rapid reduction in reliever use at the start of study
treatment and a further, gradual decline in use during the
6-month treatment period. This pattern of use was
consistent with improvement in objective assessments of
asthma control at clinic visits, and reported episodic high
use of reliever was corroborated by higher rates of
exacerbations. Thus, it appears that self-reported use of
medication was in line with other treatment outcomes.
The reduced rate of severe exacerbations, including
hospitalisations/ER treatments, with budesonide/formoterol
maintenance and reliever therapy versus high-dose salme-
terol/fluticasone confirms the findings of a recent study
conducted by Kuna and colleagues, in which budesonide/
formoterol 160/4.5mg bid plus as needed reduced the rate
of severe exacerbations by 39% and hospitalisations/ER
treatment by 39% compared with salmeterol/fluticasone
(100/500mg daily).20 The Kuna study was also a double-blind,
double-dummy study of 6 months’ duration, with similar
populations in terms of FEV1 (percent predicted) and steroid
dose at entry. The present study differs in that the design
allowed budesonide/formoterol maintenance and reliever
therapy to be tested against the maximum approved dose of
salmeterol/fluticasone (100/1000mg daily), which had been
used by the majority of patients in the GOAL study when
aiming for total control.7 Our study showed no difference in
any measure of daily symptom control between this same
maximum dose of salmeterol/fluticasone and budesonide/
formoterol maintenance and reliever therapy. The resulting
significantly lower severe exacerbation rate seen with
budesonide/formoterol maintenance and reliever therapy
without any difference in daily asthma control suggests that
better overall asthma control may be gained without
resorting to up-titration of maintenance medication and
increasing exposure to steroids if the budesonide/formoterol
maintenance and reliever therapy approach is adopted.
In conclusion, compared with the highest approved dose
of salmeterol/fluticasone plus SABA, treatment with bude-
sonide/formoterol as both maintenance and reliever ther-apy reduces the incidence of severe asthma exacerbations
and hospitalisation/ER treatment. Furthermore, this treat-
ment approach provides added protection for patients who
still have episodes of deteriorating asthma. Other measures
of asthma control were similar in the two treatment groups,
but budesonide/formoterol maintenance and reliever ther-
apy is associated with substantially less ICS exposure and is
cost effective. These results confirm that budesonide/
formoterol maintenance and reliever therapy is the most
effective management approach in patients with moderate
to severe asthma.
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